PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer.

This disease is often diagnosed only after it has metastasized throughout the body making any truly effective treatment difficult. PBI-05204 was evaluated in this patient population at five clinical sites across the USA. In addition to once again demonstrating the safety of our drug, we are pleased to announce that a partial response and several stable disease designations were obtained.